Plectranthus amboinicus attenuates inflammatory bone erosion in mice with collagen-induced arthritis by downregulation of RANKL-induced NFATc1 expression

Journal of Rheumatology

Volumn 38, Issue 9, 2011, Pages 1844-1857

  Hsu, Yu Chieh ^a   Cheng, Chia Pi ^a   Chang, Deh Ming ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Collagen induced arthritis; Nuclear factor of activated T cells c1; Osteoclast; Plectranthus amboinicus

Indexed keywords

ANTIINFLAMMATORY AGENT; COLONY STIMULATING FACTOR 1; NUCLEAR FACTOR OF ACTIVATED T CELL C PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PLANT EXTRACT; PLECTRANTHUS AMBOINICUS EXTRACT; ROSMARINIC ACID; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE EROSION; BONE MARROW CELL; CELL ACTIVITY; CELL MATURATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNOBLOTTING; INFLAMMATORY DISEASE; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PLECTRANTHUS; PLECTRANTHUS AMBOINICUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVITIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BONE DENSITY CONSERVATION AGENTS; CELL LINE; CINNAMATES; DEPSIDES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; MALE; MICE; MICE, INBRED DBA; NFATC TRANSCRIPTION FACTORS; OSTEITIS; PLANT EXTRACTS; PLECTRANTHUS; PRIMARY CELL CULTURE; RANK LIGAND;

EID: 80052314862     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101223     Document Type: Article

References (57)

1. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82. (Pubitemid 44833343)
2. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000;165:6590-8.
3. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 2002;196:77-85. (Pubitemid 34747313)
4. Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. N Engl J Med 1990;322:1483-7. (Pubitemid 20179861)
5. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-27. (Pubitemid 35396913)
6. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
7. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57. (Pubitemid 30649812)
8. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev 1992;13:66-80.
9. Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;27:1229-41. (Pubitemid 29347472)
10. Chambers TJ. Regulation of the differentiation and function of osteoclasts. J Pathol 2000;192:4-13.
11. Martin TJ, Romas E, Gillespie MT. Interleukins in the control of osteoclast differentiation. Crit Rev Eukaryot Gene Expr 1998;8:107-23. (Pubitemid 30152112)
12. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-kappa B (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappa b and c-Jun N-terminal kinase. J Biol Chem 1998;273:20551-5. (Pubitemid 28377625)
13. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-kappa B activation by the TRANCE receptor. J Biol Chem 1998; 273:28355-9. (Pubitemid 28496137)
14. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42. (Pubitemid 40852708)
15. Lerner UH. New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption. Crit Rev Oral Biol Med 2004; 15:64-81.
16. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-49. (Pubitemid 36917505)
17. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007;40:251-64. (Pubitemid 46054562)
18. Vera R, Mondon JM, Pieribattesti JC. Chemical composition of the essential oil and aqueous extract of Plectranthus amboinicus. Planta Med 1993;59:182-3. (Pubitemid 23116497)
19. Chang SL, Chang YC, Yang CH, Hong HS. Allergic contact dermatitis to Plectranthus amboinicus masquerading as chronic leg ulcer. Contact Dermatitis 2005;53:356-7.
20. Chang JM, Cheng CM, Hung LM, Chung YS, Wu RY. Potential use of Plectranthus amboinicus in the treatment of rheumatoid arthritis. Evid Based Complement Alternat Med 2007 Nov 23. [Epub ahead of print]
21. Composition and methods for treating inflammation and inflammation-related disorders by Plectranthus amboinicus extract. [Internet. Accessed June 16, 2011.] Available from: http://pharma-licensing.com/public/ outlicensing/view/11558/composition-and-methods-for-treating-inflammation-and- inflammation-related-disorders-by-plectranthus-amboinicus-extract
22. Evans KE, Fox SW. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol 2007;8:4.
23. Park MJ, Min SY, Park KS, Cho YG, Cho ML, Jung YO, et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis Res Ther 2008;10:R11.
24. Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 2003;5:R122-31.
25. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999;42:498-506. (Pubitemid 29136098)
26. Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 2005;280:35209-16. (Pubitemid 41532708)
27. Kukita T, Wada N, Kukita A, Kakimoto T, Sandra F, Toh K, et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 2004;200:941-6. (Pubitemid 39362930)
28. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005;202:345-51. (Pubitemid 41126951)
29. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, et al. Syk, c-Src, the alpha v beta 3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 2007;176:877-88.
30. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, et al. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002;30:71-7. (Pubitemid 34044303)
31. Mozar A, Haren N, Chasseraud M, Louvet L, Maziere C, Wattel A, et al. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol 2008;215:47-54. (Pubitemid 351363190)
32. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266:443-8.
33. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002;143:3105-13. (Pubitemid 34809883)
34. Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. Anat Rec 2002;268:137-46.
35. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901. (Pubitemid 35460788)
36. Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 2007;282:18245-53. (Pubitemid 47100255)
37. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002;277:41147-56. (Pubitemid 35215706)
38. van den Berg WB, van Lent PL, Joosten LA, Abdollahi-Roodsaz S, Koenders MI. Amplifying elements of arthritis and joint destruction. Ann Rheum Dis 2007;66 Suppl 3:iii45-8. (Pubitemid 350032633)
39. Scrivo R, Di Franco M, Spadaro A, Valesini G. The immunology of rheumatoid arthritis. Ann NY Acad Sci 2007;1108:312-22. (Pubitemid 47528744)
40. Lloyd M. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;339:202; author reply 3.
41. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14.
42. O'Regan RM, Gradishar WJ. Selective estrogen-receptor modulators in 2001. Oncology (Williston Park) 2001;15:1177-85, 89-90; discussion 90-4.
43. Body JJ. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 2002;30:75S-9S.
44. Tremollieres F, Lopes P. [Specific estrogen receptor modulators (SERMs)]. Presse Med 2002;31:1323-8.
45. Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003;19:395-414. (Pubitemid 36514526)
46. Lukhoba CW, Simmonds MS, Paton AJ. Plectranthus: a review of ethnobotanical uses. J Ethnopharmacol 2006;103:1-24.
47. Peake PW, Pussell BA, Martyn P, Timmermans V, Charlesworth JA. The inhibitory effect of rosmarinic acid on complement involves the C5 convertase. Int J Immunopharmacol 1991;13:853-7.
48. Osakabe N, Takano H, Sanbongi C, Yasuda A, Yanagisawa R, Inoue K, et al. Anti-inflammatory and anti-allergic effect of rosmarinic acid (RA); inhibition of seasonal allergic rhinoconjunctivitis (SAR) and its mechanism. Biofactors 2004;21:127-31. (Pubitemid 40921839)
49. Youn J, Lee KH, Won J, Huh SJ, Yun HS, Cho WG, et al. Beneficial effects of rosmarinic acid on suppression of collagen induced arthritis. J Rheumatol 2003;30:1203-7. (Pubitemid 36666341)
50. Schett G, Stolina M, Bolon B, Middleton S, Adlam M, Brown H, et al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum 2005;52:3192-201. (Pubitemid 41447102)
51. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-24. (Pubitemid 29453612)
52. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
53. Luo JL, Kamata H, Karin M. IKK/NF-kappa B signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115:2625-32. (Pubitemid 41434385)
54. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene 2006;372:92-102.
55. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004;279:45969-79. (Pubitemid 39491590)
56. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440. (Pubitemid 26130190)
57. Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 2002;13:299-313.